WallStSmart

Boston Scientific Corp (BSX)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 203724% more annual revenue ($20.07B vs $9.85M). BSX leads profitability with a 14.4% profit margin vs -10.9%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

WOK

Avoid

29

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: 1.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for WOK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

WOK1 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

WOK4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Market CapQuality
$1.46M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-6.5%2/10

ROE of -6.5% — below average capital efficiency

Revenue GrowthGrowth
-14.4%2/10

Revenue declined 14.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : WOK

The strongest argument for WOK centers on Price/Book.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : WOK

The primary concerns for WOK are Altman Z-Score, Market Cap, Return on Equity.

Key Dynamics to Monitor

BSX profiles as a growth stock while WOK is a turnaround play — different risk/reward profiles.

BSX is growing revenue faster at 15.9% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (63/100 vs 29/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

WORK Medical Technology Group LTD Ordinary Shares

HEALTHCARE · MEDICAL DEVICES · USA

WORK Medical Technology Group Ltd is a prominent player in the medical technology sector, specializing in the research, development, and commercialization of innovative healthcare solutions. The company focuses on creating advanced medical devices that significantly improve patient outcomes and meet pressing global healthcare challenges. With a strong dedication to quality and a diverse product portfolio, WORK is strategically positioned for sustained growth, making it an appealing investment choice for institutional investors aiming to capitalize on transformative developments in the healthcare industry.

Visit Website →

Want to dig deeper into these stocks?